1-3 of 3
Antoine J Boudot
Close
Sort by
Journal Articles

Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

Ran Reshef, Hyung C. Suh, Monzr M. Al Malki, Aasiya Matin, Ashish S Kothari, Allison Bell, Antoine J Boudot, Yun Wang, Nina Abelowitz, James Murray, Gavin Macbeath, Debora Barton, Shrikanta Chattopadhyay
Journal: Blood
Blood (2022) 140 (Supplement 1): 7468–7469.
https://doi.org/10.1182/blood-2022-167707
Published: 2022
Journal Articles

Discovery of TSC-101: A First-in-Class Natural HA-2-Specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy

Ribhu Nayar, Mollie M Jurewicz, Sonal Jangalwe, Hannah Bader, Kimberly M Cirelli, Andrew Basinski, Daniel Pollacksmith, Alexandra Luther, Cisem Karaca, Anna Labrozzi, Krista Daniel, Lisa Nip, Danielle Ramsdell, Amy Virbasius, Candace Perullo, Kenneth L Jahan, Sida Liao, Livio Dukaj, Alexandra Cristofaro, Shrikanta Chattopadhyay, Kenneth Olivier, Antoine J Boudot, Qikai Xu, Yifan Wang, Cagan Gurer, Gavin Macbeath
Journal: Blood
Blood (2021) 138 (Supplement 1): 1704.
https://doi.org/10.1182/blood-2021-151317
Published: 2021
Journal Articles

Product Characteristics and Multi-Arm Clinical Trial Design for TSC-100 and TSC-101, TCR-T Cells That Target Leukemia Following Hematopoietic Cell Transplantation

Shrikanta Chattopadhyay, Christopher Malcuit, Ryo Takeuchi, Emmett Hedblom, Warren Jaworowicz, Antoine J Boudot, Hannah Bader, James Murray, Gavin Macbeath
Journal: Blood
Blood (2021) 138 (Supplement 1): 3863.
https://doi.org/10.1182/blood-2021-153844
Published: 2021